| WEDNESDAY 1st OCTOBER 2025 | ||
|---|---|---|
| HALL A | ||
| Opening session | ||
| 12:30 - 13:30 | Registration and welcome coffee | |
| 13:30-13:45 | AROME - ESO WELCOME | Joseph Gligorov (France) Vladimir Todorović (Montenegro) |
| HALL A | ||
| Session 1 | Innovations in diagnostics | |
| Chairs | Dragana Bogdanović Stojanović (Serbia) & Nina Radošević (France) | |
| 14:00-14:30 | Evolutions in molecular imaging | Khaldoun Kerrou (France) |
| 14:30-15:00 | AI & Imaging & screening | Isabelle Thomassin (France) |
| 15:00-15:30 | Liquid biopsy | Radmila Janković (Serbia) |
| 15:30-16:00 | Coffee break | |
| Session 2: Innovations in locoregional treatments | ||
| Chairs: Ivan Markovic (Serbia) & Nebojša Crnogorac (Montenegro) | ||
| 16:00-16:30 | Innovation in surgery | Nada Santrač (Serbia) |
| 16:30-17:00 | Interventional radiology: are all techniques crucial? | Sanja Stojanović (Serbia) |
| 17:00-17:30 | Radiotherapy | Yazid Belkacemi (France) |
| 17:30-18:30 | Industry sponsored session – Glosarij CD – MSD KEYTRUDA and the journey from extended survival to potential cure in certain tumor types Clinical evidence and ESMO MCBS scores across indications - from advanced to early stages Moderator: Lazar Popović, Panelists: Marijana Milović-Kovačević, Timur Cerić |
|
| THURSDAY 2nd OCTOBER 2025 | ||
|---|---|---|
| HALL A | ||
| Session 3 | Gastro Intestinal cancers treatments innovations | |
| Chairs: | Nenad Mijalković (Serbia) & Milan Risteski (North Macedonia) | |
| 09:00-09:30 | News in pathology and molecular diagnosis | Filip Vukmirović (Montenegro) |
| 09:30-10:00 | News in adjuvant colorectal cancers | Biljana Kukić (Serbia) |
| 10:00-10:30 | News in metastatic colorectal cancers | Nenad Mitreski (North Macedonia) |
| 10:30-11:00 | News in non-colorectal GI cancers | Romain Cohen (France) |
| 11:00-11:30 | Coffee break | |
| Session 4: | Lung cancers treatments innovations | |
| Chairs: | Vladimir Kovčin (Serbia) & Adda Bounedjar (Algeria) | |
| 11:30-11:50 | Screening and prevention | Jelena Đekić Malbaša (Serbia) |
| 11:50-12:10 | Treatment options in inoperable localized lung cancers | Felipe De Sousa (Switzerland) |
| 12:10-12:30 | Innovations in immunotherapy for lung cancers | Timur Cerić (Bosnia & Herzegovina) |
| 12:30-12:50 | Innovations in targeted treatments for lung cancers | Sanja Pleština (Croatia) |
| 13:00-14:30 | Lunch break | |
| Session 5: | Urogenital cancers treatments innovations | |
| Chairs: | Zoran Džamić (Serbia) & Nevenka Lukovac Janjić (Montenegro) | |
| 14:45-15:05 | Optimal treatment sequences in localized prostate cancer | Dušanka Tešanović (Serbia) |
| 15:05-15:35 | Innovations in prostate and renal cancer | Lazar Popović (Serbia) |
| 15:35-15:55 | Innovations in bladder cancers | Milan Risteski (North Macedonia) |
| 15:55-16:25 | Coffee break | |
| Session 6: | Supportive care | |
| Chairs: | Sedat Turkan (Turkey) & Hassan Errihani (Morocco) | |
| 16:35-17:05 | Innovations in pain management | Tomi Kovačević (Serbia) |
| 17:05-17:35 | Cardiotoxicity in Systemic Oncology treatment | Marko Musić (Montenegro) |
| HALL B | ||
| 16:05-16:35 | Industry sponsored session – MERCK Chair: Zoran Džamić The importance of Bavencio in treatment of urothelial cancer - Zoran Džamić Efficacy and safety of Bavencio in the treatment of LA/mUC - Lazar Popović Bavencio- experiences from real clinical practice in the treatment of LA/mUC - Nevenka Lukovac Janjić | |
| 16:35-17:05 | Industry sponsored session – MEDICO PHARMACIA | |
| 17:05 -17:50 | Industry sponsored session – ASTRAZENECA EVOLVING ROLE OF CALQUENCE IN PRACTICE Lectures: Vesko Vujičić, Montenegro, Ivana Miketić, Montenegro, Nikola Bakić, Montenegro | |
| 17:50-18:20 | Industry sponsored session – AMICUS Renal Cell Carcinoma: Current Overview – Zoran Džamić Opdivo + Yervoy in RCC: Durable Outcomes and Clinical Impact – Lazar Popović 2L management of RCC: The role of Opdivo - Nevenka Lukovac Janjić | |
| FRIDAY 3rd OCTOBER 2025 | ||
|---|---|---|
| HALL A | ||
| Session 7: | Cancer and fertility | |
| Chairs: | Joseph Gligorov (France) & Zorica Tomašević (Serbia) | |
| 08:30-08:50 | Fertility preservation | Natalija Dedić Plavetić (Croatia) |
| 08:50-09:10 | Cancer during pregnancy | Snezana Šušnjar (Serbia) |
| 09:10-09:30 | Pregnancy after cancer | Snežana Crnogorac (Montenegro) |
| 09:30-09:45 | Coffee break | |
| Session 8: | Breast cancers treatments innovations | |
| Chairs: | Vladimir Todorovic (Montenegro) & Marijana Milović Kovačević (Serbia) | |
| 09:45-10:05 | Inovations in HER2 positive disease | Assia Konsoulova (Bulgaria) |
| 10:05-10:25 | Innovations in TNBC | Hamouda Boussen (Tunisia) |
| 10:25-10:45 | Innovations in HR+/HER2 neg | Ivana Božović Spasojević (Serbia) |
| 10:45-10:50 | Coffee break | |
| 10:50-12:50 | Industry sponsored session – NOVARTIS (coffee served inside) Reducing Risk and Improving Treatment Outcomes: Ribociclib in Early HR+/HER2- Breast Cancer Moderator: Vladimir Todorović Lecturers: Nikola Milašević, Marijana Milović, Joseph Gligorov |
|
| 12:55-13:55 | Industry sponsored session – ASTRA ZENECA (coffee served inside) Shaping Momentum and Destiny of Breast Cancer in the Region Chair: Lazar Popović, Serbia Lecturers and panelists: Natalija Dedić Plavetić, Croatia, Ivana Božović Spasojević, Serbia, Assia Konsoulova, Bulgaria, Nikola Milašević, Montenegro |
|
| 13:00-14:00 | Industry sponsored session – ROCHE (coffee served inside) Navigating the Complexity of Breast Cancer: From the HER2 Paradigm to PIK3CA Breakthroughs Chair: Vladimir Todorović Roche legacy of anti-HER2 treatment: Bridging Clinical Trials and Real-World Practice in Montenegro – Nada Cicmil Sarić Unmet Need in 1L PIK3CAmut HR+/HER2- BC: How can we improve patient outcomes in HR+ mBC? – Ana Cvetanović |
|
| 14:00-15:00 | Lunch break | |
| Session 9: | Gynecologic cancers treatments innovations | |
| Chairs: | Suzana Vasović (Serbia) & Gordana Bašović (Montenegro) | |
| 15:00-15:30 | Innovations in gynecological surgery | Iztok Takač (Slovenia) |
| 15:30-16:00 | Innovations in gynecological radiotherapy | Goran Marošević (Croatia) |
| 16:00-16:30 | Innovations in targeted treatments for ovarian cancers | Marijana Milović Kovačević (Serbia) |
| 16:30-17:00 | Innovations in targeted treatments for cervical and endometrial cancers | Violeta Klisarovska (North Macedonia) |
| 17:00-17:15 | Coffee break | |
| Session 10: | Head & Neck, Melanoma & CNS cancers treatments innovations | |
| Chairs: | Nikola Milašević (Montenegro) & Dušanka Tešanović (Serbia) | |
| 17:15-17:45 | Innovation in Head & Neck | Esat Mahmut Ozsahin (Switzerland) |
| 17:45-18:05 | Innovation in Melanoma | Borislava Nikolin (Serbia) |
| 18:05-18:25 | Innovation in CNS and bone cancers | Igor Stojkovski (North Macedonia) |
| 18:30-19:00 | Industry sponsored session – MEDISON Pharma The View of Uveal Melanoma - The Perspective of Patient Management Uveal Melanoma - Disease Characteristics – Borislava Nikolin, Metastatic Uveal Melanoma – Treatment Guidelines and Patient Management - Ana Cvetanović |
|
| 21:00 | Congress dinner, Banquet hall, hotel Mediteran, Bečići | |
| HALL B | ||
| 10:00-10:30 | Industry sponsored session – PFIZER Integrating Lorlatinib Into First-Line ALK+ NSCLC Treatment Focus on Lorlatinib; Transforming Patient Outcomes in ALK+ NSCLC – Nikola Milašević Optimizing Long-term Treatment with Lorlatinib: Balancing Efficacy and Safety – Ana Delić Vukićević |
|
| SATURDAY 4th OCTOBER 2025 | ||
|---|---|---|
| AROME Montenegro Consensus conference | ||
| Prioritizing Strategies for Access to Cancer Care and Innovations in Emerging Countries | ||
| (Endorsed by Oncology Section - Serbian Medical Society) | ||
| Joseph Gligorov (France), Vladimir Todorovic (Montenegro), Eniu Alexandru (Romania) & Paula Tsoutsou (Greece) | ||
| 10:00-12:00 | Expert discussion and voting session | |
| 12:00-12:15 | Closing remarks | |